Background -Bacterial infections of the lower airways during an exacerbation in patients with asthma or chronic obstructive pulmonary disease (COPD) may be the cause of an exacerbation or the consequence of a viral infection or an increase in airways limitation. To determine whether bacterial infection is an important component in the pathogenesis of an exacerbation, the effects of antimicrobial treatment must be studied. Methods -Patients with asthma or COPD seen in general practice were studied in a double blind randomised manner to investigate whether the antimicrobial drugs amoxicillin (500 mg three times daily), cotrimoxazole (960 mg twice daily), or a placebo, each when added to a short course of oral corticosteroids, can accelerate recovery from exacerbations. Patients were instructed to contact their own physician early in the morning when complaints of increased shortness of breath, wheezing, or exacerbations of cough with or without sputum production occurred. (Thorax 1995;50:758-763) 
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Background -Bacterial infections of the lower airways during an exacerbation in patients with asthma or chronic obstructive pulmonary disease (COPD) may be the cause of an exacerbation or the consequence of a viral infection or an increase in airways limitation. To determine whether bacterial infection is an important component in the pathogenesis of an exacerbation, the effects of antimicrobial treatment must be studied. Methods -Patients with asthma or COPD seen in general practice were studied in a double blind randomised manner to investigate whether the antimicrobial drugs amoxicillin (500 mg three times daily), cotrimoxazole (960 mg twice daily), or a placebo, each when added to a short course of oral corticosteroids, can accelerate recovery from exacerbations. Patients were instructed to contact their own physician early in the morning when complaints of increased shortness of breath, wheezing, or exacerbations of cough with or without sputum production occurred. Treatment effects were evaluated over the next 14 days by studying symptom scores (wheeze, dyspnoea, cough with and without mucus production, and awakening with dyspnoea), peak expiratory flow values ( Exacerbations in patients with asthma or chronic obstructive pulmonary disease (COPD) involve a worsening of symptoms such as dyspnoea and cough, often with purulent sputum. These patients usually receive antimicrobial treatment in combination with a short course of prednisolone, which is the standard treatment for exacerbations ofasthma and COPD in the Netherlands. However, the alleged bacterial infection of the lower airways during the exacerbation might be the cause of the exacerbation, or the consequence of a viral infection or the increase in airways limitation.
In many studies"A which have included microbiological evaluation, including viral and bacteriological cultures and serological assays, a correlation has been observed between the purulence of sputum and the occurrence of an exacerbation.
To obtain evidence of the involvement of Patients with asthma or COPD were instructed to contact their physician, as they would normally do, early in the morning when increased shortness of breath, wheezing, or exacerbations of cough, with or without sputum, occurred. An exacerbation was patient initiated and defined as a sustained increase in dyspnoea with or without sputum production, despite increasing their normal twice daily inhaled therapy to 3-4 times daily. A seven day course of either amoxicillin (500 mg three times daily), co-trimoxazole (960 mg twice daily), or placebo tablets was given in a randomised, double blind manner. Since co-trimoxazole was given twice daily, a third placebo tablet was added to the daily medication. Placebo tablets were given three times daily and tasted either like amoxicillin or co-trimoxazole, maintaining the double blind nature ofthe trial. As prednisolone (35 mg on day 1, reduced by 5 mg daily) during an exacerbation is the standard treatment prescribed by most physicians in the Netherlands for asthma and COPD, it was used as well. During the following 14 days symptom scores and peak expiratory flow (PEF) values were monitored. Bacteriological examination of sputum samples was made at the onset of an exacerbation and 7, 21, and 35 days afterwards.
Peak expiratory flow
Daily recordings of PEF2' were made during a seven day baseline period and for two weeks from the start of the exacerbation using a Wright peak flow minimeter (Clement Clarke International, London, UK). Each patient recorded three successive measurements three times per day -early in the morning, before and after their first inhalation medication, and before their second inhalation medication in the evening. The highest outcome of three successive efforts in the morning, before the daily medication, was recorded for analysis.
Treatment failures
Criteria for treatment failure were revisits to the physician with worsening symptoms within 35 days of the start of treatment. The patient's physician had to decide, if bacterial infection was suspected, whether antimicrobial treatment would be justified based on clinical history and PEF values.
Symptoms
The following systems were recorded daily by the patient during a two week period on a four point scale of severity ranging from 0 to 3: (1) wheeze or dyspnoea; (2) cough with mucus production; (3) cough without mucus production; and (4) The macroscopic appearance and the Gram stain were examined by the same technician and physician during the entire study. "Viridans streptococci" (not further identified a-haemolytic streptococci) were regarded as "oropharyngeal flora" as they make up the main proportion of the oropharyngeal flora. 22 25 1 2 3 4 5 6 7 8 9 10 11 12 * Daily record during a two week period on a four point scale of severity ranging from 0 to 3 of (1) wheeze or dyspnoea;
(2) cough with mucus production; (3) cough without mucus production; and (4) awakening with complaints of dyspnoea.
antibiotics, and by 0-06 (0 045) points per day in the placebo group.
Temperature
There was no significant increase in sublingual temperature in the exacerbation period.
Investigation of sputum Fifty of the 71 patients (70%) with an exacerbation produced sputum. Potentially pathogenic microorganisms were isolated from 24 of 50 (48%) of the samples, whereas 19 of 50 (38%) samples had a purulent appearance. On days 7, 21, and 35 after onset of the exacerbation there were four sputum samples which were purulent, irrespective of the medication given.
During the exacerbation eight of 50 (16%) patients produced sputum with evidence of a lower respiratory tract infection that met the requirements of > 105 potentially pathogenic microorganisms in culture in association with > 25 leucocytes and <5 epithelial cells in Gram stain. Two of these patients produced mucoid sputum and six purulent sputum. Two of the latter six received placebo treatment and four antibiotics. In the sputum samples of the two placebo treated patients one showed no potentially pathogenic microorganisms during the follow up period while the other did not return for follow up.
Treatment failures
Six out of 71 patients (8 5%) consulted with their physician again within 4-24 days of the start of treatment because of worsening of symptoms. All received an antibiotic. These six patients were equally distributed among the three randomisation groups. Two of these patients, one in the amoxicillin group and one in the placebo group, had a second exacerbation 4-7 days after starting treatment. No potentially pathogenic microorganisms were found in cultures of either sputum sample.
Possible confounding variables
The patients with asthma were not concentrated in any particular group. Three out of 10 patients with asthma entered the amoxicillin group, three the co-trimoxazole group, and four were in the placebo group. At the onset of their exacerbation PEF % predicted was significantly higher in asthmatic patients than in those with COPD, but there were no differences in recovery rates. Symptom scores were comparable at the onset of exacerbation, but improved faster in individuals with asthma than in those with COPD.
The distribution of individuals with purulent or non-purulent sputum samples in the three medication regimens was: eight of 12 patients in the amoxicillin group, four of nine in the co-trimoxazole group, and seven of 10 patients in the placebo group.
No significant difference was found between patients with asthma or COPD in the as- This is the first study of an exacerbation in patients with asthma or COPD who are normally treated by a general practitioner. When symptom scores, PEF values, sublingual temperature, and sputum cultures were monitored, no differences in recovery rates were observed when antibiotics were added to a short course of prednisolone. Thus, bacterial infection of the lower airways is rarely the cause or consequence of symptoms and signs of an increase in airways limitation during an exacerbation. Treatment with prednisolone alone appears to be sufficient in ambulatory general practice patients with mild to moderate obstructive airways disease to eliminate the bronchial obstruction. Diminishing the inflammatory process is probably sufficient. However, these results should not be extrapolated to patients with more severe forms of obstructive airways disease.
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